FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602464207> ?p ?o ?g. }

• W2602464207 endingPage "873" @default.
• W2602464207 startingPage "867" @default.
• W2602464207 abstract "Active surveillance (AS) is an option for men with low-risk prostate cancer (PCa). PTEN and ERG have been considered as potential biomarkers of PCa progression and survival.To study the role of ERG and PTEN status in the Prostate Cancer Research International: Active Surveillance (PRIAS) trial diagnostic biopsies (DBxs) in predicting surveillance discontinuation and adverse surgical findings in subsequent radical prostatectomy (RP).A total of 231 patients were recruited to the PRIAS between 2007 and 2013 in Helsinki. DBx tissue for immunohistochemistry (IHC) was available from 190 patients. Tissue microarrays (TMAs) were constructed from 57 specimens of subsequent RPs. DBxs containing grade group (GG) 1 PCa and RP TMA sections were stained with ERG and PTEN antibodies, and scored as either negative or positive.Outcomes were followed up by biopsy GG upgrade (GG ≥ 2) and protocol-based treatment change, as well as adverse findings in RP (GG ≥ 3 or pathological stage≥3). Clinical variables and biomarker status in DBx were correlated in Cox regression analysis and cumulative survival in Kaplan-Meier analysis, and finally, Gray's competing risk analysis was performed and nonprotocol-based discontinuation was considered as a competing event.In both uni- and multivariate Cox regression analyses, only the number of positive cores in the DBx, the number of rebiopsy sessions, and PTEN status at diagnosis were significantly associated with rebiopsy GG upgrade, treatment change, and adverse histopathology in RP. In Kaplan-Meier analysis, PTEN loss was associated with a shorter time to GG upgrade and treatment change. Patients with PTEN loss had a higher probability for protocol-based discontinuation but not for competing risk factors compared with patients with intact PTEN. Biopsy ERG status was concordant with RP TMA ERG status, while PTEN was not. Limitations include a retrospective analysis of prospective cohort data.PTEN status at diagnosis is a potential biomarker for identifying patients with PCa on AS with a high risk for progression or adverse findings on subsequent RP.A simple diagnostic biopsy-based analysis of PTEN status may help identify patients with high risk for prostate cancer progression." @default.
• W2602464207 created "2017-04-07" @default.
• W2602464207 creator A5021740564 @default.
• W2602464207 creator A5037739817 @default.
• W2602464207 creator A5040800642 @default.
• W2602464207 creator A5064643435 @default.
• W2602464207 creator A5084456779 @default.
• W2602464207 date "2018-12-01" @default.
• W2602464207 modified "2023-10-17" @default.
• W2602464207 title "PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance" @default.
• W2602464207 cites W1540017758 @default.
• W2602464207 cites W1966230453 @default.
• W2602464207 cites W1973804704 @default.
• W2602464207 cites W1982109854 @default.
• W2602464207 cites W2000060994 @default.
• W2602464207 cites W2009087111 @default.
• W2602464207 cites W2044167977 @default.
• W2602464207 cites W2054074987 @default.
• W2602464207 cites W2065042304 @default.
• W2602464207 cites W2087045997 @default.
• W2602464207 cites W2110569728 @default.
• W2602464207 cites W2117050434 @default.
• W2602464207 cites W2121158863 @default.
• W2602464207 cites W2150095882 @default.
• W2602464207 cites W2152440352 @default.
• W2602464207 cites W2160714232 @default.
• W2602464207 cites W2172201105 @default.
• W2602464207 cites W2173477069 @default.
• W2602464207 cites W2385742736 @default.
• W2602464207 cites W2417621301 @default.
• W2602464207 cites W2439583849 @default.
• W2602464207 cites W2515442448 @default.
• W2602464207 cites W2523396458 @default.
• W2602464207 cites W2524254168 @default.
• W2602464207 doi "https://doi.org/10.1016/j.euf.2017.03.004" @default.
• W2602464207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28753869" @default.
• W2602464207 hasPublicationYear "2018" @default.
• W2602464207 type Work @default.
• W2602464207 sameAs 2602464207 @default.
• W2602464207 citedByCount "32" @default.
• W2602464207 countsByYear W26024642072017 @default.
• W2602464207 countsByYear W26024642072018 @default.
• W2602464207 countsByYear W26024642072019 @default.
• W2602464207 countsByYear W26024642072020 @default.
• W2602464207 countsByYear W26024642072021 @default.
• W2602464207 countsByYear W26024642072022 @default.
• W2602464207 countsByYear W26024642072023 @default.
• W2602464207 crossrefType "journal-article" @default.
• W2602464207 hasAuthorship W2602464207A5021740564 @default.
• W2602464207 hasAuthorship W2602464207A5037739817 @default.
• W2602464207 hasAuthorship W2602464207A5040800642 @default.
• W2602464207 hasAuthorship W2602464207A5064643435 @default.
• W2602464207 hasAuthorship W2602464207A5084456779 @default.
• W2602464207 hasBestOaLocation W26024642071 @default.
• W2602464207 hasConcept C103796816 @default.
• W2602464207 hasConcept C118487528 @default.
• W2602464207 hasConcept C121608353 @default.
• W2602464207 hasConcept C126322002 @default.
• W2602464207 hasConcept C143998085 @default.
• W2602464207 hasConcept C185592680 @default.
• W2602464207 hasConcept C190283241 @default.
• W2602464207 hasConcept C193270364 @default.
• W2602464207 hasConcept C197934379 @default.
• W2602464207 hasConcept C2775934546 @default.
• W2602464207 hasConcept C2777609662 @default.
• W2602464207 hasConcept C2778715236 @default.
• W2602464207 hasConcept C2779466945 @default.
• W2602464207 hasConcept C2780192828 @default.
• W2602464207 hasConcept C2780827179 @default.
• W2602464207 hasConcept C50382708 @default.
• W2602464207 hasConcept C55493867 @default.
• W2602464207 hasConcept C71924100 @default.
• W2602464207 hasConcept C86554907 @default.
• W2602464207 hasConceptScore W2602464207C103796816 @default.
• W2602464207 hasConceptScore W2602464207C118487528 @default.
• W2602464207 hasConceptScore W2602464207C121608353 @default.
• W2602464207 hasConceptScore W2602464207C126322002 @default.
• W2602464207 hasConceptScore W2602464207C143998085 @default.
• W2602464207 hasConceptScore W2602464207C185592680 @default.
• W2602464207 hasConceptScore W2602464207C190283241 @default.
• W2602464207 hasConceptScore W2602464207C193270364 @default.
• W2602464207 hasConceptScore W2602464207C197934379 @default.
• W2602464207 hasConceptScore W2602464207C2775934546 @default.
• W2602464207 hasConceptScore W2602464207C2777609662 @default.
• W2602464207 hasConceptScore W2602464207C2778715236 @default.
• W2602464207 hasConceptScore W2602464207C2779466945 @default.
• W2602464207 hasConceptScore W2602464207C2780192828 @default.
• W2602464207 hasConceptScore W2602464207C2780827179 @default.
• W2602464207 hasConceptScore W2602464207C50382708 @default.
• W2602464207 hasConceptScore W2602464207C55493867 @default.
• W2602464207 hasConceptScore W2602464207C71924100 @default.
• W2602464207 hasConceptScore W2602464207C86554907 @default.
• W2602464207 hasIssue "6" @default.
• W2602464207 hasLocation W26024642071 @default.
• W2602464207 hasLocation W26024642072 @default.
• W2602464207 hasOpenAccess W2602464207 @default.
• W2602464207 hasPrimaryLocation W26024642071 @default.
• W2602464207 hasRelatedWork W1921191893 @default.

• next